Short answer
Penumbra Inc (PEN) filed its Q1 2018 10-Q quarterly report on May 8, 2018 for the quarter ended Mar 31, 2018.
Penumbra Inc Q1 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $102.7M, up 40.3% YoY from $73.2M
- Neuro revenue $71.4M, up 42.2%, best-performing segment
- Peripheral Vascular revenue $31.3M, up 36.2%, slower segment growth
- Gross margin 64.8% vs 65.2% YoY, operating margin 3.9% vs negative 2.8%
- Cash $52.8M, operating cash flow $10.7M, capital expenditures $2.8M; liquidity sufficient for at least 12 months
Risk Factors
- No material changes or newly identified risks since the December 31, 2017 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 7, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 7, 2018
- Q3 2017 10-QFiled Nov 7, 2017
- Q2 2017 10-QFiled Aug 8, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q1 2016 10-QFiled May 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.